OTC Birth Control Not Good For Women's Health, Natural Family Planning Group Says
Executive Summary
SymptoPro Fertility Education focuses comments to FDA on potential side effects from Opill, suggesting its use could be linked to increased breast cancer risk, depression and ectopic pregnancy. Guttmacher Institute supports approval, saying “adolescents have most to gain.”
You may also be interested in...
Catholic Group Asserts Alarm About Teen Access Among Doubts About Safety Of OTC Birth Control
In comment among dozens posted at deadline shortly before FDA advisory panel meeting in May on HRA Pharma’s Opill proposal, Pro-Family Women says, “American women’s typical use of contraceptives, when put into real-world practice, often do not prevent pregnancy.” Other advocacy and professional groups’ comments near deadline urge approval to expand access.
Another State Approves Pharmacy Access To Hormonal Contraceptives
Indiana allows pharmacists, through a standing order from state health agency, to prescribe some hormonal contraceptives in pill or patch form. American College of Obstetricians and Gynecologists among recent supporters of OTC approval in comments to FDA.
Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024
Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.